Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not

被引:41
作者
Tefferi, Ayalew [1 ]
Mesa, Ruben A. [1 ]
Pardanani, Animesh [1 ]
Hussein, Kebede [1 ]
Schwager, Susan [1 ]
Hanson, Curtis A. [2 ]
Steensma, David P. [1 ]
机构
[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA
[2] Mayo Clin, Div Hematopathol, Rochester, MN 55905 USA
关键词
PROGNOSTIC-FACTORS; IRON-OVERLOAD; MYELODYSPLASTIC SYNDROMES; MYELOID METAPLASIA; DEPENDENT ANEMIAS; SCORING SYSTEM; DEFERASIROX; ICL670;
D O I
10.1002/ajh.21391
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Serum ferritin level at diagnosis was available in 185 patients with primary myelofibrosis (PMF); twenty-two (12%) patients had serum ferritin >1,000 ng/mL and 32 (17%) were red blood cell (RBC) transfusion-dependent. As expected, RBC transfusion need and increased serum ferritin displayed strong correlation (P < 0.0001); in addition, the latter but not the former correlated with advanced age (P < 0.0001). During median follow-up of 28 months (range 0.5-231), peak serum ferritin levels exceeded 1,000 ng/mL in 41 (22%) patients. On multivariable analysis that included age as a covariate, RBC transfusion need at diagnosis (P < 0.0001), but not increased serum ferritin or transfusion load, predicted shortened survival. The prognostic relevance of RBC transfusion need was independent of the International Prognostic Scoring System and was also illustrated for leukemia-free survival (P = 0.003). In PMF, the presence of a more severe erythropoietic defect, and not iron overload, has additional adverse prognostic value. Am. J. Hematol. 84:265-267, 2009. (C) 2009 Wiley-Liss, Inc.
引用
收藏
页码:265 / 267
页数:3
相关论文
共 16 条
[11]   Deferasirox in MDS patients with transfusion-caused iron overload-a phase-II study [J].
Metzgeroth, Georgia ;
Dinter, Dietmar ;
Schultheis, Beate ;
Dorn-Beineke, Alexandra ;
Lutz, Kira ;
Leismann, Oliver ;
Hehlmann, Rudiger ;
Hastka, Jan .
ANNALS OF HEMATOLOGY, 2009, 88 (04) :301-310
[12]   A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade®, ICL670) in patients with transfusion-dependent anemias and iron-overload:: a Phase I study in Japan [J].
Miyazawa, Keisuke ;
Ohyashiki, Kazuma ;
Urabe, Akio ;
Hata, Tomoko ;
Nakao, Shinji ;
Ozawa, Keiya ;
Ishikawa, Takayuki ;
Kato, Junji ;
Tatsumi, Yoichi ;
Mori, Hiraku ;
Kondo, Midori ;
Taniguchi, Junsuke ;
Tanii, Hiromi ;
Rojkjaer, Lisa ;
Omine, Mitsuhiro .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 88 (01) :73-81
[13]   Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670):: a 1-yr prospective study [J].
Porter, John ;
Galanello, Renzo ;
Saglio, Giuseppe ;
Neufeld, Ellis J. ;
Vichinsky, Elliott ;
Cappellini, Maria Domenica ;
Olivieri, Nancy ;
Piga, Antonio ;
Cunningham, Melody J. ;
Soulieres, Denis ;
Gattermann, Norbert ;
Tchernia, Gilbert ;
Maertens, Johan ;
Giardina, Patricia ;
Kwiatkowski, Janet ;
Quarta, Giovanni ;
Jeng, Michael ;
Forni, Gian Luca ;
Stadler, Michael ;
Cario, Holger ;
Debusscher, Louisette ;
Della Porta, Matteo ;
Cazzola, Mario ;
Greenberg, Peter ;
Alimena, Giuliana ;
Rabault, Bertrand ;
Gathmann, Insa ;
Ford, John Malcolm ;
Alberti, Daniele ;
Rose, Christian .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 80 (02) :168-176
[14]  
STEENSMA DP, LEUK RES IN PRESS
[15]   Validation and comparison of contemporary prognostic models in primary myelofibrosis - Analysis based on 334 patients from a single institution [J].
Tefferi, Ayalew ;
Huang, Jocelin ;
Schwager, Susan ;
Li, Chin-Yang ;
Wu, Wenting ;
Pardanani, Animesh ;
Mesa, Ruben A. .
CANCER, 2007, 109 (10) :2083-2088
[16]  
Vardiman JW, 2001, WHO CLASSIFICATION T, P17